Fed Report Calls on NIH to Blaze Personalized Medicine Trail


Personalized Medicine Watch by John Russell

October 14, 2008 | It’s a busy time on the personalized medicine front. The recently-released federal government report, Priorities for Personalized Medicine, is gradually attracting attention. The state of Wisconsin last week jumped into the race to become a center for personalized medicine. And a group of technology providers has joined Scripps Translational Science Institute (STSI) to study to what extent people make behavioral changes when they are provided with genetic screening and information about their various risk factors.

Back in 2001, the President’s Council of Advisors on Science and Technology were instructed to develop   suggested policy around personalized medicine’s needs. The result, Priorities for Personalized Medicine, is not all that profound—“HHS, should join with the private sector to create a public/private sector ‘Personalized Medicine R&D Roadmap’ for coordinating discovery and translational research in personalized medicine”—but it’s a start.

NIH is urged to take in lead in directing “critical investments in the enabling tools and resources essential to moving beyond genomic discoveries to personalized medicine products and services of patient and public benefit.” Specifically, the report calls on NIH to spur efforts to develop an integrated nationwide network of standardized biospecimen repositories and to fund academic/industry projects addressing biomarker standardization, statistical methods.

Meanwhile Wisconsin governor Jim Doyle today announced the Wisconsin Genomics Initiative, a collaborative research effort among the Marshfield Clinic, Medical College of Wisconsin (MCW), University of Wisconsin School of Medicine and Public Health (UWSMPH) and UW-Milwaukee (UWM). Wisconsin has long been a leader in genomic research. The Marshfield Clinic has undertaken the largest population-based genetic research project in the country which approximately 20,000 people have contributed their DNA and given researchers access to their complete electronic health records.

The other big news last week was the announcement that MicrosoftNavigenics, and Affymetrix would join forces with the Scripps Translational Science Institute (STSI) to launch a novel research study to assess the behavioral impact of personal genetic testing. The goal of the study is to discover if participating in personal genomic testing improves people’s health by encouraging them to make positive lifestyle decisions and medical monitoring.

The study will offer genetic scans by Navigenics to up to 10,000 employees, friends, and family of the nonprofit Scripps Health system in San Diego and monitor participants’ changes in behavior for two decades. Participants will report their lifestyle changes at 3- and 12-month intervals after they receive their Navigenics results. They will also take part in periodic health surveys over the next two decades. A complete database of genomic and clinical information will be maintained at the Scripps Genomic Medicine program. For more read the Bio-IT World article on the program.

Related Links
Priorities for Personalized Medicine report:
http://www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf.

The Wisconsin initiative:
http://www.eurekalert.org/pub_releases/2008-10/mc-gda101008.php
http://www.forbes.com/feeds/ap/2008/10/10/ap5537035.html

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .